Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Benaroya Research Institute
With
Cell Genesys
Sanofi
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patients must have clinical stage 1-3 disease and no radiographic evidence of metastatic disease
Nomogram Prediction: Patients must have a Kattan nomogram predicted probability of being free from biochemical progression at 5 years after surgery of \<60%.
You may not be if
Concurrent or prior treatment with radiation, cytotoxic or biologic therapy for prostate cancer, prior hormonal therapy (except finasteride or dutasteride for obstructive voiding symptoms)
Male patients unwilling to use effective means of contraception are excluded. Contraception should be continued for 3 months after treatment.
Prior malignancy will not exclude the patient. (Patients can not have active cancer or be undergoing active treatment). The Principal Investigator will make final decision regarding eligibility since the end point is pathological complete response.
Clareo Health | Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer
